

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

 $\label{licensed:the patent has been licensed to an entity, whether \\$

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Hernández 1



Section 1. Identifying	Information	
1. Given Name (First Name) José Luis	2. Surname (Last Name) Hernández	3. Date 12-May-2020
4. Are you the corresponding author	or? ✓ Yes No	
5. Manuscript Title Reducing residual thrombotic ri	sk in patients with peripheral artery disease. I	mpact of the COMPASS trial.
6. Manuscript Identifying Number	(if you know it)	
Section 2. The Work U	nder Consideration for Publication	
any aspect of the submitted work (i statistical analysis, etc.)? Are there any relevant conflicts	ncluding but not limited to grants, data monitorin	(government, commercial, private foundation, etc.) for g board, study design, manuscript preparation,
Section 3. Relevant fin	ancial activities outside the submitted	work.
of compensation) with entities a		ave financial relationships (regardless of amount or each entity; add as many lines as you need by during the 36 months prior to publication.
Are there any relevant conflicts If yes, please fill out the appropr		
Name of Entity	Grant? Personal Non-Financial Fees? Support?	Other? Comments
Bayer, Daiichi Sankyo, Sanofi, Abbie, a AMGEN	nd 🗌 🔽	consulting fees and/or lectures honoraria
Section 4. Intellectual	Property Patents & Copyrights	
Do you have any patents, wheth	ner planned, pending or issued, broadly releva	ant to the work? ☐ Yes ✓ No

Hernández 2



Cartion 5	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Hernández re	eports personal fees from Bayer, Daiichi Sankyo, Sanofi, Abbie, and AMGEN, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Hernández 3



Section 1.	Identifying Inform	ation			
1. Given Name (Fii Francisco S.	rst Name)	2. Surname (Last Name) Lozano		3. Date 12-May-2020	
4. Are you the cor	responding author?	☐ Yes ✓ No		ding Author's Name Hernández	
5. Manuscript Title Reducing residua		tients with peripheral ar	tery disease. Iı	Impact of the COMPASS trial.	
6. Manuscript Ider	ntifying Number (if you kn	ow it)			
Section 2.	The Work Under Co	onsideration for Pub	lication		
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to grants,		(government, commercial, private foundation, etc. g board, study design, manuscript preparation,	.) for
Section 3.	Relevant financial	activities outside the	submitted	work.	
of compensation clicking the "Add Are there any rel) with entities as descri	bed in the instructions. bort relationships that west? Yes No	Use one line fo	ave financial relationships (regardless of amou or each entity; add as many lines as you need l during the 36 months prior to publication.	
Name of Entity		Grant? Personal N	on-Financial Support	Other? Comments	
	and Sanofi-Aventis; and yer Health Care, Daiichi Kline, Leo Pharma,			compensation for advisory-board membership	
Section 4.	Intellectual Proper	ty Patents & Copyr	rights		
Do you have any	patents, whether plani	ned, pending or issued,	broadly releva	ant to the work? Yes V No	

Lozano 2



Cartina P	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
	ts personal fees from Boehringer-Ingelheim, Bayer Health Care, Daiichi Sankyo, Rovi and Sanofi-Aventis; I from Bayer Health Care, Daiichi Sankyo, Glaxo Smith Kline, Leo Pharma, Menarini, Rovi, and Sanofi-Aventis, Initial work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Lozano 3



Section 1. Identifying Infor	mation	
1. Given Name (First Name) Vincent	2. Surname (Last Name) Riambau	3. Date 12-May-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name José Luis Hernández
5. Manuscript Title Reducing residual thrombotic risk in p	atients with peripheral art	ery disease. Impact of the COMPASS trial.
6. Manuscript Identifying Number (if you l	know it)	
Section 2. The Work Under (Consideration for Publi	cation
any aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of inte	ng but not limited to grants, d	n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financia	l activities outside the	submitted work.
of compensation) with entities as desc	ribed in the instructions. Ueport relationships that we rest? 📝 Yes 🗌 No	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .
Name of Entity	Grant? Personal No	n-Financial Other? Comments
Bayer, Sanofi and AstraZeneca		consulting fees
Section 4. Intellectual Prope	erty Patents & Copyri	ghts
Do you have any patents, whether pla	nned, pending or issued, b	roadly relevant to the work? Yes V No

Riambau 2



Section 5.			
Section 5.	Relationships not covered above		
	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?		
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):		
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest		
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.		
Section 6.	Disclosure Statement		
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box		
Dr. Riambau rep	orts personal fees from Bayer, Sanofi and AstraZeneca, outside the submitted work; .		

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Riambau 3



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Manuel	2. Surname (Last Name) Almendro-Delia	3. Date 12-May-2020
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name José Luis Hernández
5. Manuscript Title Reducing residual thrombotic risk in pa	tients with peripheral arte	ery disease. Impact of the COMPASS trial.
6. Manuscript Identifying Number (if you kr	now it)	_
Section 2. The Work Under C	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descr	ibed in the instructions. Use port relationships that we lest?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .
Name of Entity	Grant? Personal Not	n-Financial Other? Comments
Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Eli Lilly, Glaxo Smith Kline, Daiichi-Sankyo, Rovi Pharmaceuticals, and Sanofi Aventis, and grants support from Astra Zeneca		consulting fees and/or lectures honoraria
Section 4. Intellectual Brance		
Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes V No

Almendro-Delia 2



Continu F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
	elia reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Eli Kline, Daiichi-Sankyo, Rovi Pharmaceuticals, and Sanofi Aventis, and grants support from AstraZeneca, nitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Almendro-Delia 3



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Juan	2. Surname (Last Name) Cosín-Sales	3. Date 12-May-2020
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name José Luis Hernández
5. Manuscript Title Reducing residual thrombotic risk in pa	tients with peripheral arte	ery disease. Impact of the COMPASS trial.
6. Manuscript Identifying Number (if you kr	now it)	
Section 2. The Work Under Co	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflicts of interest lf yes, please fill out the appropriate info		
Name of Entity	Grant	n-Financial other? Comments
Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Pfizer-BMS		consulting fees
Section 4. Intellectual Proper	ty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes V No

Cosín-Sales 2



Cartina 5	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Cosín-Sales r the submitted w	reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Pfizer-BMS, outside ork; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Cosín-Sales 3



Section 1.	Identifying Inform	nation		
1. Given Name (Fi Sergi	rst Name)	2. Surname (Last Name) Bellmunt-Montoya	3. Date 12-May-2020	
4. Are you the cor	responding author?	Yes Vo	Corresponding Author's Name José Luis Hernández	
5. Manuscript Title Reducing residu		atients with peripheral art	tery disease. Impact of the COMPASS trial.	
6. Manuscript Ider	ntifying Number (if you kı	now it)		
Section 2.	The Work Under C	onsideration for Publ	ication	
any aspect of the s statistical analysis, Are there any rel	ubmitted work (including	g but not limited to grants, c	m a third party (government, commercial, private foundation, etc.) data monitoring board, study design, manuscript preparation,	l for
Section 3.	Relevant financial	activities outside the	submitted work.	
of compensation clicking the "Ado Are there any rel) with entities as descr	ibed in the instructions. Uport relationships that we est? Yes No	hether you have financial relationships (regardless of amour Use one line for each entity; add as many lines as you need b ere present during the 36 months prior to publication .	
Name of Entity		Grant	on-Financial Support? Comments	
Bayer			consulting fees	
Section 4.	Intellectual Prope	rty Patents & Copyr	ights	
Do you have any	patents, whether plan	ned, pending or issued, b	oroadly relevant to the work? Yes V No	

Bellmunt-Montoya 2



Section 5. Polationships not solvered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Bellmunt-Montoya reports personal fees from Bayer, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Bellmunt-Montoya 3



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Javier	2. Surname (Last Name) Garcia-Alegria	3. Date 12-May-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name José Luis Hernández
5. Manuscript Title Reducing residual thrombotic risk in pa	tients with peripheral arte	ery disease. Impact of the COMPASS trial.
6. Manuscript Identifying Number (if you kn	ow it)	
Section 2. The Work Under Co	onsideration for Publi	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descri	bed in the instructions. U	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflicts of intered If yes, please fill out the appropriate info		
Name of Entity	Grant? Personal No	on-Financial Other? Comments
Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo		consulting fees and/or lectures honoraria
Section 4. Intellectual Proper	ty Patents & Copyri	ghts
Do you have any patents, whether plant	ned, pending or issued, bi	roadly relevant to the work? Yes V No

Garcia-Alegria 2



Coation F					
Section 5.	Relationships not covered above				
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?				
Yes, the follo	Yes, the following relationships/conditions/circumstances are present (explain below):				
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest				
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.				
Section 6.	Disclosure Statement				
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box				
Dr. Garcia-Alegri submitted work;	a reports personal fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, outside the				

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Garcia-Alegria 3



Section 1. Identifying Inform	ation		
1. Given Name (First Name) Xavier	2. Surname (Last Name) Garcia-Moll		3. Date 12-May-2020
4. Are you the corresponding author?	Yes ✓ No	Corresponding Autho	
5. Manuscript Title Reducing residual thrombotic risk in pa	tients with peripheral arte	ery disease. Impact of	the COMPASS trial.
6. Manuscript Identifying Number (if you kn	ow it)		
		_	
Section 2. The Work Under Co	onsideration for Publi	cation	
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da		
Section 3. Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	bed in the instructions. Use ort relations hips that we est? Yes No	se one line for each er	ntity; add as many lines as you need by
Name of Entity	Grant	n-Financial Other?	Comments
Astra-Zeneca, Bayer, Boehringer-Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb / Pfizer.			consulting fees and/or lectures honoraria and/or advisory-board membership
Section 4. Intellectual Proper	ty Patents & Copyri	ghts	
Do you have any patents, whether plant	ned, pending or issued, bi	roadly relevant to the	work? ☐ Yes ✓ No

Garcia-Moll 2



Cardina E				
Section 5.	Relationships not covered above			
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?			
Yes, the following relationships/conditions/circumstances are present (explain below):				
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest			
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.			
Section 6.	Disclosure Statement			
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box			
	eports personal fees from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Daiichi Sankyo, Bristol-Myers outside the submitted work; .			

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Garcia-Moll 3



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Juan José	2. Surname (Last Name) Gomez-Doblas	3. Date 12-May-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name José Luis Hernández
5. Manuscript Title Reducing residual thrombotic risk in pa	tients with peripheral arte	ry disease. Impact of the COMPASS trial.
6. Manuscript Identifying Number (if you kn	now it)	
		_
Section 2. The Work Under Co	onsideration for Public	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflicts of intered		
Name of Entity	Grant	n-Financial other? Comments
Bayer, Boehringer Ingelheim, AstraZeneca, Daiichi Sankyo.		consulting fees and/or lectures honoraria
Section 4. Intellectual Proper	ty Patents & Copyric	ghts
Do you have any patents, whether plant	ned, pending or issued, br	oadly relevant to the work? Yes V No

Gomez-Doblas 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Gomez-Dobl submitted work;	as reports personal fees from Bayer, Boehringer Ingelheim, AstraZeneca, Daiichi Sankyo., outside the

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Gomez-Doblas 3



Section 1. Identifying Inform	nation		
1. Given Name (First Name) José Ramón	2. Surname (Last Name) Gonzalez-Juanatey		3. Date 12-May-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Auth José Luis Hernánde	
5. Manuscript Title Reducing residual thrombotic risk in pa	atients with peripheral arte	ery disease. Impact of	the COMPASS trial.
6. Manuscript Identifying Number (if you k	now it)		
		_	
Section 2. The Work Under C	onsideration for Publi	cation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, da		ent, commercial, private foundation, etc.) for tudy design, manuscript preparation,
Section 3. Relevant financial	activities outside the	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the instructions. U	se one line for each e	
Are there any relevant conflicts of inter			
If yes, please fill out the appropriate inf	ormation below.		
Name of Entity	Grant	n-Financial Other?	Comments
Bayer			honoraria for lectures and advisory board
Section 4. Intellectual Prope	rty Patents & Copyri	ghts	
Do you have any patents, whether plan	ned, pending or issued, b	oadly relevant to the	work? Yes V No

Gonzalez-Juanatey 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Gonzalez-Juanatey reports personal fees from Bayer, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Gonzalez-Juanatey 3



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Carmen	2. Surname (Last Name) Suarez Fernández		3. Date 12-May-2020
4. Are you the corresponding author?	Yes Vo	Corresponding Auth José Luis Hernánde	
5. Manuscript Title Reducing residual thrombotic risk in pa	atients with peripheral arte	ery disease. Impact of	the COMPASS trial.
6. Manuscript Identifying Number (if you k	now it)		
		_	
Section 2. The Work Under C	onsideration for Publi	cation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, da		ent, commercial, private foundation, etc.) for tudy design, manuscript preparation,
Section 3. Relevant financial	activities outside the	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the instructions. U	se one line for each e	
Are there any relevant conflicts of inter			
If yes, please fill out the appropriate inf	ormation below.		
Name of Entity	Grant	n-Financial Other?	Comments
Bayer			consulting fees and lectures honoraria
Section 4. Intellectual Prope	rty Patents & Copyri	ghts	
Do you have any patents, whether plan	ned, pending or issued, b	oadly relevant to the	work? Yes V No

Suarez Fernández 2



Section 5. Polationships not solvered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Suarez Fernández reports personal fees from Bayer, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Suarez Fernández 3